Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.04.2024 | Case report

AZD-1222/Natalizumab/Ocrelizumab

Brachial and lumbosacral plexitis and lack of efficacy

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Fontes-Villalba A, et al. ACUTE PLEXITIS AFTER ASTRAZENECA COVID-19 VACCINATION IN TWO IMMUNOCOMPROMISED PATIENTS. BMJ Neurology Open 4 (Suppl.): A67 abstr. 2459, Aug 2022. Available from: URL: https://dx.doi.org/10.1136/bmjno-2022-ANZAN.183 [abstract] Fontes-Villalba A, et al. ACUTE PLEXITIS AFTER ASTRAZENECA COVID-19 VACCINATION IN TWO IMMUNOCOMPROMISED PATIENTS. BMJ Neurology Open 4 (Suppl.): A67 abstr. 2459, Aug 2022. Available from: URL: https://dx.doi.org/10.1136/bmjno-2022-ANZAN.183 [abstract]
Metadaten
Titel
AZD-1222/Natalizumab/Ocrelizumab
Brachial and lumbosacral plexitis and lack of efficacy
Publikationsdatum
01.04.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-56720-5

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Erlotinib

Case report

Multiple drugs

Case report

Pasireotide